5'URR regulatory polymorphisms are associated with the risk of developing gliomas.

Background: Human leukocyte antigen G (HLA-G) belongs to non-classical MHC class I molecules that is involved in the suppression of immune response. As HLA-G plays important role in the maintenance of fetal tolerance, its overexpression has been associated with tumor progression. For the regulation of HLA-G levels, genetic variants within the 5' upstream regulatory region (5'URR) are of crucial importance. Our study aimed to analyze the association between 16 5'URR variants, sHLA-G level and clinical variables in glioma patients.

Methods: We investigated 59 patients with gliomas (mean age 54.70 ± 15.10 years) and 131 healthy controls (mean age 41.45 ± 9.75 years). Patient's blood was obtained on the day of surgical treatment. The 5'URR polymorphisms were typed by direct sequencing and the plasma level of sHLA-G assessed by ELISA.

Results: Haploblock within 5'URR consisting of -762T, -716G, -689G, -666T, -633A, followed by -486C and -201A alleles were significantly more frequent in patients with gliomas than in the controls ( < 0.05). No correlation of 5'URR variants with sHLA-G plasma level was found. Analysis of 5'URR variants with main clinical variables in patients with grade IV gliomas revealed that haploblock carriers of -762CT, -716TG, -689AG, -666GT, -633GA, -486AC, -477GC, -201GA followed by -369AC carriers tend to have lower age at onset as compared to other genotype carriers ( = 0.04).

Conclusion: Our results suggest genetic association of 5'URR variants with risk of developing gliomas and possible contribution of HLA-G to disease pathology.